MOUNTAIN VIEW, Calif., Nov. 1, 2012 /PRNewswire/ -- The rising incidence of acute cardiac rhythm-related disorders is prompting device manufacturers to innovate their cardiac rhythm management (CRM) devices. Technological advances such as device miniaturization, development of smaller durable batteries, and biocompatible materials casing enhances patient comfort and reduces mortality and morbidity rate in patients.
New analysis from Frost & Sullivan's (http://www.technicalinsights.frost.com) Cardiac Rhythm Management (CRM) Devices—Demand to Manage Global R&D Efforts research finds that less invasive procedures and constant product updates drive the adoption of CRM devices.
If you are interested in more information on this research, please email Britni Myers, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
The latter part of the 20th century witnessed a revolution in medical devices with smaller, superior features and capabilities. The advent of implantable pacemakers, implantable cardioverter defibrillators (ICD), and cardiac resynchronization therapy (CRT) improved physicians' diagnostic capabilities.
"The new technology allows clinicians to monitor patients continuously without needing frequent office visits, in turn lowering the burden of follow-up care," said Frost & Sullivan Research Analyst Darshana De. "Further evolution of CRM technology encourages the use of home-based healthcare devices that provide improved safety to patients."
These new devices are likely to find high uptake as an aging baby boomer population as well as sedentary American and European lifestyles result in disorders such as obesity and diabetes, which expand the cardiovascular patient pool. As pe
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved